Hims & Hers Health (NYSE:HIMS) Shares Gap Down After Insider Selling

Hims & Hers Health, Inc. (NYSE:HIMS) shares gapped down before the market opened on Thursday following insider selling activity. The stock had previously closed at $26.95, but opened at $25.16. Hims & Hers Health shares last traded at $26.27, with a volume of 6,054,360 shares trading hands.

Specifically, CFO Oluyemi Okupe sold 11,581 shares of the firm’s stock in a transaction dated Tuesday, April 15th. The shares were sold at an average price of $28.50, for a total transaction of $330,058.50. Following the completion of the sale, the chief financial officer now directly owns 118,960 shares in the company, valued at approximately $3,390,360. This trade represents a 8.87 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Soleil Boughton sold 3,236 shares of the business’s stock in a transaction dated Monday, April 14th. The shares were sold at an average price of $28.72, for a total transaction of $92,937.92. Following the completion of the transaction, the insider now owns 162,898 shares in the company, valued at $4,678,430.56. The trade was a 1.95 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In other news, insider Soleil Boughton sold 4,151 shares of the firm’s stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $45.14, for a total transaction of $187,376.14. Following the completion of the sale, the insider now owns 166,134 shares in the company, valued at $7,499,288.76. This trade represents a 2.44 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Analysts Set New Price Targets

A number of research analysts recently commented on the company. Truist Financial decreased their price objective on Hims & Hers Health from $39.00 to $33.00 and set a “hold” rating on the stock in a report on Thursday, April 10th. Canaccord Genuity Group upped their price target on Hims & Hers Health from $38.00 to $68.00 and gave the company a “buy” rating in a research note on Wednesday, February 19th. Citigroup reissued a “sell” rating on shares of Hims & Hers Health in a research report on Wednesday, April 2nd. BTIG Research began coverage on shares of Hims & Hers Health in a research report on Tuesday, January 7th. They issued a “buy” rating and a $35.00 target price on the stock. Finally, Bank of America lifted their price target on shares of Hims & Hers Health from $21.00 to $22.00 and gave the company an “underperform” rating in a research report on Tuesday, March 18th. Two equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $38.25.

Hims & Hers Health Stock Performance

The company’s 50-day simple moving average is $37.59 and its 200 day simple moving average is $30.56. The company has a market cap of $6.05 billion, a PE ratio of 61.91 and a beta of 1.65.

Hims & Hers Health (NYSE:HIMS) last released its earnings results on Monday, February 24th. The company reported $0.11 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.09 by $0.02. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. The firm had revenue of $481.14 million during the quarter, compared to analyst estimates of $494.56 million. Analysts forecast that Hims & Hers Health, Inc. will post 0.29 EPS for the current year.

Hedge Funds Weigh In On Hims & Hers Health

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Crewe Advisors LLC acquired a new stake in Hims & Hers Health in the fourth quarter valued at approximately $28,000. Raleigh Capital Management Inc. increased its position in shares of Hims & Hers Health by 1,100.0% in the 4th quarter. Raleigh Capital Management Inc. now owns 1,200 shares of the company’s stock valued at $29,000 after purchasing an additional 1,100 shares during the last quarter. Blume Capital Management Inc. raised its holdings in shares of Hims & Hers Health by 100.0% in the 4th quarter. Blume Capital Management Inc. now owns 1,200 shares of the company’s stock valued at $29,000 after purchasing an additional 600 shares in the last quarter. UMB Bank n.a. lifted its position in shares of Hims & Hers Health by 247.5% during the 1st quarter. UMB Bank n.a. now owns 1,310 shares of the company’s stock worth $39,000 after purchasing an additional 933 shares during the last quarter. Finally, Smartleaf Asset Management LLC grew its stake in shares of Hims & Hers Health by 4,415.6% during the fourth quarter. Smartleaf Asset Management LLC now owns 1,445 shares of the company’s stock worth $36,000 after purchasing an additional 1,413 shares in the last quarter. Hedge funds and other institutional investors own 63.52% of the company’s stock.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.